ieumBio has been selected as one of eight companies for the 2026 Startup Innovation Catalyst at the Longevity Investors Conference (LIC 2026), taking place September 14-17 in Gstaad, Switzerland.

The Startup Innovation Catalyst brings together selected companies across the longevity ecosystem, spanning therapeutics, diagnostics, AI-enabled health solutions, and longevity research platforms.

ieumBio will showcase its rapid vertebrate validation platform, which leverages short-lived vertebrate models to accelerate the evaluation of longevity and healthspan interventions and generate translational insights for longevity drug development.

We look forward to engaging with global investors, industry leaders, and innovators at LIC 2026.